Home >> Research Area >>Tyrosine Kinase/Adaptors>>PDGFR>> Tyrphostin AG 1296

Tyrphostin AG 1296

PDGFR inhibitor,selective and ATP-competitive CAS# 146535-11-7

Tyrphostin AG 1296

Catalog No. BCC1195----Order now to get a substantial discount!

Product Name & Size Price Stock
Tyrphostin AG 1296: 5mg $104 In Stock
Tyrphostin AG 1296: 10mg Please Inquire In Stock
Tyrphostin AG 1296: 20mg Please Inquire Please Inquire
Tyrphostin AG 1296: 50mg Please Inquire Please Inquire
Tyrphostin AG 1296: 100mg Please Inquire Please Inquire
Tyrphostin AG 1296: 200mg Please Inquire Please Inquire
Tyrphostin AG 1296: 500mg Please Inquire Please Inquire
Tyrphostin AG 1296: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Tyrphostin AG 1296

Number of papers citing our products

Chemical structure

Tyrphostin AG 1296

3D structure

Chemical Properties of Tyrphostin AG 1296

Cas No. 146535-11-7 SDF Download SDF
PubChem ID 2049 Appearance Powder
Formula C16H14N2O2 M.Wt 266.29
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 6 mg/mL (22.53 mM) in DMSO
Chemical Name 6,7-dimethoxy-2-phenylquinoxaline
SMILES COC1=C(C=C2C(=C1)N=CC(=N2)C3=CC=CC=C3)OC
Standard InChIKey QNOXYUNHIGOWNY-UHFFFAOYSA-N
Standard InChI InChI=1S/C16H14N2O2/c1-19-15-8-12-13(9-16(15)20-2)18-14(10-17-12)11-6-4-3-5-7-11/h3-10H,1-2H3
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Tyrphostin AG 1296

DescriptionTyrphostin AG 1296 is a selective inhibitor of platelet-derived growth factor receptor (PDGFR) with IC50 value of 0.3 μM-0.5 μM.
TargetsPDGFR    
IC500.3 μM-0.5 μM     

Tyrphostin AG 1296 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Tyrphostin AG 1296 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Tyrphostin AG 1296

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.7553 mL 18.7765 mL 37.553 mL 75.1061 mL 93.8826 mL
5 mM 0.7511 mL 3.7553 mL 7.5106 mL 15.0212 mL 18.7765 mL
10 mM 0.3755 mL 1.8777 mL 3.7553 mL 7.5106 mL 9.3883 mL
50 mM 0.0751 mL 0.3755 mL 0.7511 mL 1.5021 mL 1.8777 mL
100 mM 0.0376 mL 0.1878 mL 0.3755 mL 0.7511 mL 0.9388 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Tyrphostin AG 1296

Tyrphostin AG 1296 is a selective inhibitor of platelet-derived growth factor receptor (PDGFR) with IC50 value of 0.3μM-0.5μM [1].

Tyrphostin AG 1296 is an ATP-competitive inhibitor of PDGFR. It binds to PDGFR, causing a conformational change at the ATP-binding site. In the in vitro assay, it potently inhibits the ligand-induced autophosphorylation of PDGF receptor in Swiss 3T3 cell membranes. Tyrphostin AG 1296 does not affect the EGF receptor when the concentration is up to 100μM. Tyrphostin AG 1296 also inhibits the mitogenesis induced by PDGF but not EGF or insulin. It reversibly inhibits PDGF-induced DNA synthesis with a mean IC50 value of 1.5μM. Besides that, tyrphostin AG 1296 inhibits PDGF-induced cell growth with IC50 value of 3.2μM in Swiss 3T3 cells [1, 2].

References:
[1] Kovalenko M, Gazit A, Böhmer A, et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Research, 1994, 54(23): 6106-6114.
[2] Kovalenko M, Rönnstrand L, Heldin C H, et al. Phosphorylation site-specific inhibition of platelet-derived growth factor β-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry, 1997, 36(21): 6260-6269.

Featured Products
New Products
 

References on Tyrphostin AG 1296

Additive effect by combination of Akt inhibitor, MK-2206, and PDGFR inhibitor, tyrphostin AG 1296, in suppressing anaplastic thyroid carcinoma cell viability and motility.[Pubmed:24665203]

Onco Targets Ther. 2014 Mar 14;7:425-32.

The phosphatidylinositol-3-kinase/Akt pathway and receptor tyrosine kinases regulate many tumorigenesis related cellular processes including cell metabolism, cell survival, cell motility, and angiogenesis. Anaplastic thyroid carcinoma (ATC) is a rare type of thyroid cancer with no effective systemic therapy. It has been shown that Akt activation is associated with tumor progression in ATC. Here we observed the additive effect between an Akt inhibitor (MK-2206) and a novel platelet-derived growth factor receptor inhibitor (Tyrphostin AG 1296) in ATC therapy. We found an additive effect between MK-2206 and Tyrphostin AG 1296 in suppressing ATC cell viability. The combination of MK-2206 and Tyrphostin AG 1296 induces additive apoptosis, additive suppression of the Akt signaling pathway, as well as additive inhibition of cell migration and invasion of ATC cells. Furthermore, the combination of MK-2206 and Tyrphostin AG 1296 induced additive suppression of ATC tumor growth in vivo. In summary, our studies suggest that the combination of Akt and receptor tyrosine kinase inhibitors may be an efficient therapeutic strategy for ATC treatment, which might shed new light on ATC therapy.

Tyrphostin AG 1296 induces glioblastoma cell apoptosis in vitro and in vivo.[Pubmed:26788146]

Oncol Lett. 2015 Dec;10(6):3429-3433.

Glioblastoma is the most common type of malignant human brain tumor. Currently available chemotherapies for glioblastoma focus on targeting tyrosine kinases. However, the existing inhibitors of tyrosine kinases have not produced the therapeutic outcomes that were anticipated. In order to investigate the viability alternative chemotherapeutic agents in this disease, the present study examined the anticancer effects of Tyrphostin AG 1296, focusing on its involvement in apoptosis in glioblastoma cells. The study aimed to identify whether Tyrphostin AG 1296 affects glioblastoma cell growth by inducing cell apoptosis. To achieve this, cell viability, propidium iodide analysis and cell invasion assay were used to measure cell growth, cell apoptosis and cell migration of human glioblastoma cells. The results showed that Tyrphostin AG 1296 treatment reduced cell viability and suppressed migration of human glioblastoma cells. It was also demonstrated that Tyrphostin AG 1296 induced cell apoptosis in vitro. Finally, Tyrphostin AG 1296 was also shown to significantly inhibit the growth of glioblastoma cells and to increase tumor cell apoptosis in vivo. These findings suggest that Tyrphostin AG 1296 induces apoptosis, thereby reducing cell viability and capacity for migration of glioblastoma cells.

Description

Tyrphostin AG 1296 is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.

Keywords:

Tyrphostin AG 1296,146535-11-7,Natural Products,PDGFR, buy Tyrphostin AG 1296 , Tyrphostin AG 1296 supplier , purchase Tyrphostin AG 1296 , Tyrphostin AG 1296 cost , Tyrphostin AG 1296 manufacturer , order Tyrphostin AG 1296 , high purity Tyrphostin AG 1296

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: